Facts and figures
ICON is a global provider of outsourced development services
ICON has approximately 42,250 employees in 106 locations in 55 countries as at September 30, 2024. In addition to its own global network of offices, ICON can provide service delivery in a total of 93 countries globally, through locally based staff who work from home, and partnerships with local third-party providers. ICON offers a broad range of specialised solutions to assist pharmaceutical, biotechnology, medical device and government and public health organisations to bring new treatments to market faster. Our solutions span the entire lifecycle of product development, across a broad range of therapeutic areas, and can be adapted to suit small local trials or large global programs. We develop innovative technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.
Facts about ICON
About ICON
Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.
Company history
Organic growth bolstered through a number of strategic acquisitions which have broadened our service portfolio and have added scale to existing services.
Leadership team
ICON has assembled a leadership team with extensive industry experience.
Press releases
ICON's press releases.
Financial figures
- Quarter three 2024 revenue of $2,030.0 million. Quarter three adjusted EBITDA of $418.8 million or 20.6% of revenue.
- Full year revenue in 2023 was $8,120.2 million. This represents a year on year increase of 4.9% on a reported basis and 4.6% on a constant currency basis.
- Full-year 2024 financial revenue guidance in the range of $8,260 - $8,300 million, representing a year over year increase of 1.7% to 2.2%. Full-year 2024 adjusted earnings per share* guidance in the range of $13.90 - $14.10, representing a year over year increase of 8.7% to 10.2%.